NEW PUBERTY BLOCKER ADVICE, SAME OLD AFFIRMATIVE MODEL
Gary Geelhoed

The National Health and Medical Research Council’s interim advice on the use of puberty suppressants has landed as a conditional recommendation that GnRH agonists “can be considered” for under-18s with gender incongruence who have started puberty and want the treatment, after shared decision-making.

It is not a strong endorsement, but neither is it a meaningful tightening. In practice it reads as continuity with the affirmative model already operating in several Australian clinics but written by the NHMRC Gender Guidelines Development Committee and not by the panel that actually examined the evidence.

What the document does not do is more striking than what it does. It offers almost no wider framing of the clinical problem.

From essentially non-existent 30 years ago, referrals of adolescents (predominantly natal females) to specialist services rose sharply from the mid-2010s, accelerating after widespread smartphone and social media adoption around 2012.

During the 22 years until 2012 when I was director of the emergency department at Princess Margaret Hospital for Children in Perth, of the one million plus patients, I was not made aware of one adolescent who thought they were in the wrong body. This is a recent, sex-reversed phenomenon relative to the historically rare, early-onset, mostly male pattern of childhood gender dysphoria.

The advice does not explore social and cultural drivers, peer and online influences or the high rates of co-occurring autism, trauma, same-sex attraction and mental health conditions documented in recent cohorts. Neither does it examine the natural history of untreated adolescent-onset gender dysphoria. Older studies of children with gender dysphoria showed high rates of desistance through puberty; the current adolescent-onset presentation has a different profile yet the advice treats persistent incongruence as the default starting point rather than something whose trajectory is still poorly characterised.

The independent Evidence Evaluation Report commissioned by the NHMRC as part of the review largely confirms what systematic reviews for Britain’s Cass Review, the UK National Institute for Health and Care Excellence and others have already found.

Certainty of evidence is low or very low for key psychosocial outcomes. Meta-analyses show little to no important change in gender dysphoria or body image during treatment. Mental health and functioning effects are uncertain, limited by uncontrolled before-after designs, confounding and short follow-up. Bone-density accrual is compromised during suppression; long-term skeletal, cognitive and reproductive consequences remain poorly quantified.

The report is careful: “Although it is usual to report on implications for practice in a systematic review, we have not done so here since this falls within the remit of the Gender Guidelines Development Committee.”

That division of labour is the structural problem. The evidence team was not permitted to draw clinical conclusions. It states: “Each stage of the review has been informed by the expertise of people with lived experience, members of the Committee and members of the Reference Panel.

“However, the review team does not include authors who identify as trans, have previous experience undertaking research on trans health, or are health professionals caring for people who are trans and gender diverse. We recognise that this influences our world view, and interpretation of the evidence.”

The conclusions then were written by the Gender Guidelines Development Committee, not the independent panel.

Among the GGDC members is Kenneth Pang, consultant pediatrician and research lead at the Royal Children’s Hospital Melbourne Gender Service, leader of the Transgender Health Research Group at the Murdoch Children’s Research Institute, co-author of the 2018 Australian Standards of Care and Treatment Guidelines, member of AusPATH, and frequent speaker at WPATH and related conferences. He has more than 90 publications on the topic and has long advocated an affirmative approach.

Other members bring relevant clinical expertise, but the committee’s composition and the fact it alone translated the low-certainty evidence into a conditional recommendation for continued use create an obvious risk that pre-existing clinical practice shaped the interpretation more than the evidence did. Given the final recommendations are from trans advocates, not the independent panel, it raises the question of why bother with a review in the first place.

Looking at puberty suppressants in isolation further distorts the picture. Observational data shows the large majority of adolescents who start blockers (commonly cited figures exceed 90 per cent to 98 per cent in clinic cohorts) proceed to cross-sex hormones. Once that pathway is taken, fertility is often permanently compromised, especially if suppression began at Tanner stage 2, and many later undergo surgery.

Treating blockers as a reversible “pause” while the evidence shows high progression rates, and while the advice declines to engage with untreated natural history, understates the practical irreversibility for most of those who start.

Emerging evidence from Finland examining nationwide data shows not only does the affirmative approach not help but results in worse psychological outcomes.

The result is an interim document that acknowledges uncertainty in the fine print, then recommends a process that largely preserves existing practice.

States that have already restricted new initiations (Queensland, Northern Territory) now face pressure to align with national advice that the independent evidence reviewers were explicitly told not to interpret.

A process that separates the evidence from the people allowed to draw conclusions from it, and that omits the rapid epidemiological shift and the high continuation rates, is not the rigorous, independent assessment the public was led to expect. The consultation period is the remaining opportunity to correct that.

Gary Geelhoed is a retired pediatrician and researcher who served as chief medical officer of Western Australia and directed the emergency department of the Princess Margaret Hospital for Children, which was succeeded by the Perth Children’s Hospital, home to a gender clinic.